Fig. 1 · Structure
Documents & Downloads
Nε-(Carboxymethyl)-L-lysine
Advanced Glycation End Product
Nε-(Carboxymethyl)-L-lysine (CML) is an advanced glycation end product that primarily targets cellular pathways involved in inflammation and cancer progression. CML significantly upregulates the expression of PLK1 and CEP20, while activating RAGE and the ERK/NFκB signaling cascade. This compound drives centrosome amplification and is implicated in the malignant transformation of hepatocytes, promoting hepatocellular carcinoma development. Additionally, CML induces epithelial-mesenchymal transition in osteosarcoma cells, enhancing their migratory and invasive capabilities, making it a crucial reagent for cancer research and studies on glycation effects.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 5746-04-3 |
| Applications | Advanced Glycation End Product |
| Formula | C8H16N2O4 |
| Molecular Weight | 204.22 |
| Synonyms | CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine |
| SMILES | C(CCNCC(=O)O)C[C@@H](C(=O)O)N |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.